AC Immune (NASDAQ:ACIU) Rating Reiterated by HC Wainwright

AC Immune (NASDAQ:ACIU – Get Rating)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $16.00 price objective on the stock.

Separately, StockNews.com assumed coverage on AC Immune in a report on Thursday. They issued a “hold” rating for the company.

AC Immune Stock Down 3.9 %

Shares of AC Immune stock opened at $2.22 on Friday. The firm has a market cap of $185.48 million, a price-to-earnings ratio of -2.36 and a beta of 0.59. The business has a fifty day simple moving average of $2.34 and a 200-day simple moving average of $2.51. AC Immune has a fifty-two week low of $1.68 and a fifty-two week high of $4.84.

Institutional Investors Weigh In On AC Immune

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of AC Immune by 1.6% during the first quarter. BlackRock Inc. now owns 292,273 shares of the company’s stock valued at $1,169,000 after purchasing an additional 4,685 shares during the last quarter. Kingsbury Capital Investment Advisors LLC lifted its holdings in shares of AC Immune by 44.6% during the third quarter. Kingsbury Capital Investment Advisors LLC now owns 27,291 shares of the company’s stock valued at $86,000 after purchasing an additional 8,423 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of AC Immune by 2.3% during the first quarter. Renaissance Technologies LLC now owns 452,490 shares of the company’s stock valued at $1,810,000 after purchasing an additional 10,300 shares during the last quarter. Banque Cantonale Vaudoise lifted its holdings in shares of AC Immune by 92.6% during the fourth quarter. Banque Cantonale Vaudoise now owns 42,488 shares of the company’s stock valued at $86,000 after purchasing an additional 20,432 shares during the last quarter. Finally, Platinum Investment Management Ltd. lifted its holdings in shares of AC Immune by 2.2% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,082,462 shares of the company’s stock valued at $2,208,000 after purchasing an additional 23,000 shares during the last quarter. 16.78% of the stock is owned by hedge funds and other institutional investors.

About AC Immune

(Get Rating)

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.